Metagenomi, a genetic medicines company with a versatile portfolio of next-generation gene editing tools, announced the completion of an up-sized and oversubscribed $175 million Series B financing. This brings the ‹‹total amount of funding for the company to $300 million.

The Series B financing was led by PFM Health Sciences, Farallon Capital Management, and a leading global investment firm. Additional new investors include Eventide Asset Management, Deep Track Capital, Frazier Life Sciences, Pura Vida Investments, Irving Investors, Millennium Management, Surveyor Capital (a Citadel company), Marshall Wace, Novo Holdings A/S, and Bristol Myers Squibb. This financing round also included investment from strategic partner Moderna, as well as existing investors RA Capital Management, Leaps by Bayer, and Humboldt Fund, amongst others.